Nhlbi trans-omics for precision medicine (topmed) for the centralized omics resource (core)
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N92023D00016
- Awardee
-
New York Genome Center, Inc. UEI WKPTJDWG2C68
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 4 $9,185,286 obligated
Award facts
- Opportunity
-
- NHLBI Trans-Omics for Precision Medicine (TOPMed) Pre-Solicitation · 75N92022R0108 · Posted May 20, 2022
- Combined order value
-
- $9,185,286 Current, with exercised options
- $17,301,061 Potential, with all options
- Last date to order 31% complete
- IDV ceiling 2% used
- $500,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- B599 Special Studies/Analysis- Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 13 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Heart Lung and Blood Institute awarded an indefinite-delivery contract to New York Genome Center, Inc. on September 14, 2023, with a ceiling of $500 million and ultimate completion on September 13, 2033. This is a single-award, non-setaside vehicle supporting the Trans-Omics for Precision Medicine (TOPMed) Centralized Omics Resource initiative.
The IDIQ funds centralized omics resource services to support the NHLBI's precision medicine research portfolio, including complex data analysis, integration, and management of large-scale genomic and health datasets. A capability questionnaire was posted May 20, 2022, with responses due June 10, 2022, as the originating pre-solicitation activity.
Performance is located in New York, NY. The period of performance runs from September 14, 2023 through September 13, 2033.
NHLBI has issued four delivery orders under this IDIQ totaling approximately $17.3 million to date. The most recent delivery order, issued September 28, 2026, is a firm fixed-price award of $5.86 million for centralized omics resource core services with completion targeted September 27, 2030. A prior $7.0 million firm fixed-price RNA-sequencing task order was issued September 23, 2024, with completion September 22, 2027. An additional $3.7 million delivery order for centralized omics resource core services was issued September 23, 2025, completing September 22, 2027. A foundational $742,360 RNA-sequencing delivery order was issued September 28, 2023, completing September 27, 2027. All orders are firm fixed-price with no subcontractor engagement reported.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N92023D00016?
75N92023D00016 was awarded to New York Genome Center, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 14, 2023.
How much is contract 75N92023D00016 worth?
Orders under 75N92023D00016 have obligated $9,185,286. Their combined potential value, with all options, is $17,301,061. 75N92023D00016's own ceiling is $500,000,000.
How many orders have been placed under contract 75N92023D00016?
4 orders have been placed under 75N92023D00016, the latest on September 28, 2026.
Who can order from contract 75N92023D00016?
75N92023D00016 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N92023D00016 competed?
The extent of competition for 75N92023D00016 was full and open competition. The government received 13 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV